[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586747":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":70,"collaborators":10,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":10,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"\"Triple negative\" adul B-cell ALL",null,"Prospective and retrospective cohorts.",[13],"Other: \"Triple negative\" adul B-cell ALL",[15],{"type":6,"name":9,"description":16,"armGroupLabels":17,"otherNames":10},"Samples will be studied with conventional techniques to classify and define properly the disease: morphology, immunophenotype, immunohistochemistry (IHC), conventional Cytogenetic Fluorescence in Situ Hybridization (FISH) will be used when appropriate.\n\n● Isolation of Mononuclear cells\n\nThe following research methodologies will be applied:\n\n* Next Generation Sequencing\n* Flow cytometry analysis of 3C-up B-ALL top three markers\n* Gene expression profile analysis\n* Copy number Alterations analysis\n* In vitro studies",[9],[19],{"name":20,"affiliation":21,"role":22},"Giovanni Martinelli, Prof","IRST IRCCS","STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Oriana Nanni, Dr","CONTACT","+39 0543739100","oriana.nanni@irst.emr.it",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Anna Ferrari, Dr","0543739909","anna.ferrari@irst.emr.it",[34,50,60],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Irst Irccs","RECRUITING","Meldola","FC","47014","Italy","IT",{"type":43,"coordinates":44},"Point",[45,46],12.0626,44.12775,{"lat":46,"lon":45},[49],{"name":30,"role":26,"phone":10,"phoneExt":10,"email":10},{"facility":51,"status":36,"city":52,"state":53,"zip":54,"country":40,"countryCode":41,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Ospedale S. Maria delle Croci RAVENNA","Ravenna","RA","48121",{"type":43,"coordinates":56},[57,58],12.20121,44.41344,{"lat":58,"lon":57},{"facility":61,"status":36,"city":62,"state":63,"zip":64,"country":40,"countryCode":41,"cosmosGeoPoint":65,"geoPoint":69,"contacts":10},"Ospedale Infermi","Rimini","RN","47923",{"type":43,"coordinates":66},[67,68],12.56528,44.05755,{"lat":68,"lon":67},{"type":71,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100586747","triple-negative-adult-b-cell-acute-lymphoblastic-leukemia---trineg-all-100586747",false,"NCT06919393","\"Triple Negative\" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL","\"Triple Negative\" Adult B-cell Acute Lymphoblastic Leukemia: Molecular Characterization, Identification and New Stratification","TRINEG-ALL","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study;\n* Patients with new diagnosis and\u002For relapse\u002Fs of primary or secondary B-ALL;\n* Negative for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements;\n* Participant is willing and able to give informed consent for participation in the study;\n* Male or Female, aged \\>18 years;\n* Availability of clinical data.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* B-ALL positive for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements.\n\nLow blast percentage (\\\u003C70%) samples could be excluded for molecular evaluations, not for cytofluorimetric analyses;","ALL","18 Years",{"count":83,"type":84},60,"ESTIMATED","OBSERVATIONAL","It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the context of clinical practice, independently from the decision to include the patient in the study.",[88],"Leukemia, Lymphoblastic",[90,91,92],"lymphoblastic acute leukemia (LAL)","triple negative","B cell","2025-04-07",{"date":95,"type":96},"2025-04-09","ACTUAL",{"date":98,"type":96},"2019-10-23",{"date":100,"type":84},"2026-01",{"name":5,"class":6},3]